DermConsult

This study assessed the link between depressive symptoms in real-world patients with psoriasis to help identify characteristics for those at risk. What were the findings? To learn more, join Dr. Charles Turck as he speaks with Dr. Neda Shahriari, Board-Certified Dermatologist at Brigham and Women’s Hospital in Boston, Massachusetts.

To gain a better understanding of the different treatment attributes that patients with moderate-to-severe atopic dermatitis value most, a discrete choice experiment was conducted. And now, the results are in, with itch control being the top attribute. Joining Dr. Raj Chovatiya to share this and other key findings from his research that was featured as a poster at the 2023 Fall Clinical Dermatology conference is Dr. Steven Feldman, Professor of Dermatology, Pathology, Social Sciences, and Health Policy at the Wake Forest University School of Medicine in Winston-Salem, North Carolina.

Due to the evolving treatment landscape, the way we think about treating adult and elderly patients with atopic dermatitis has shifted. So what are some special considerations we need to think about when selecting a treatment option for long-term control, and how can we best involve patients in the decision-making process? Joining Dr. Raj Chovatiya to help answer these and other key questions in atopic dermatitis care is Dr. Melinda Gooderham, Medical Director for the SKiN Center for Dermatology in Peterborough, Ontario.

The biologics we know are revolutionary treatments for our patients with psoriasis and now other inflammatory skin diseases. So how do biosimilars play a part in the evolving treatment of psoriasis? Learn more with Dr. Raj Chovatiya as he dives further into biosimilars with Dr. Steve Feldman, Professor of Dermatology, Pathology, Social Sciences, and Health Policy at the Wake Forest University School of Medicine in Winston-Salem, North Carolina.

When managing atopic dermatitis, it’s up to the patient to determine how much therapeutic intervention they want to pursue, which underscores the importance of applying shared decision-making to practice. Joining Dr. Raj Chovatiya to share their perspectives on how we can utilize shared decision-making in atopic dermatitis care are Dr. Matthew Zirwas and Mr. Douglas DiRuggiero. Dr. Zirwas founded Bexley Dermatology Research Clinic in Columbus, Ohio where he specializes in adult eczema, and Mr. DiRuggiero is a certified physician assistant at the Skin Cancer and Cosmetic Dermatology Center in Rome, Georgia.

The discovery of the IL-23 pathway has revolutionized the treatment of psoriasis. Learn more about the current state of IL-23 inhibition in psoriasis management with Dr. Raj Chovatiya and Dr. George Han, Associate Professor in the Department of Dermatology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell in Uniondale, New York.

The atopic dermatitis treatment landscape has evolved over the past several years. To catch up on the current treatment options available and the novel therapies in development, Dr. Raj Chovatiya speaks with Drs. James Song and Jennifer Soung. Dr. Song is the Director of Clinical Research for Frontier Dermatology Partners in Everett, Washington, and Dr. Soung is the Director of Clinical Research at Southern California Dermatology in Santa Ana, California.

Our understanding of TYK2’s role in the pathophysiology of psoriasis has recently evolved, leading to new treatment options like deucravacitinib. Deucravacitinib is the first approved TYK2 inhibitor approved for moderate to severe plaque psoriasis. Learn more about this treatment option and the role of TYK2 with Dr. Raj Chovatiya and Dr. George Han, Associate Professor in the Department of Dermatology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell in Uniondale, New York.

Atopic dermatitis is more than a disease of the skin. It’s a complex and heterogeneous inflammatory disease mediated by multiple T-cell–driven inflammatory pathways, like the OX40 pathway, leading to chronic and persistent symptoms and significant burden.^1-4 Explore the heterogeneity of atopic dermatitis and the importance of OX40 signaling in disease pathogenesis with Dr Charles Turck and Dr. Jonathan Silverberg, Professor and Director of Clinical Research and the Director of Patch Testing at George Washington University School of Medicine and Health Sciences.

References:

1. Silverberg JI. Clinical Management of Atopic Dermatitis. 1st ed. 2018.
2. Ratchataswan T, et al. J Allergy Clin Immunol Pract. 2021;9:1053-1065.
3. Weidinger S, et al. Nat Rev Dis Primers. 2018;4:1.
4. De Bruyn Carlier T, et al. J Autoimmun. 2021;120:102634.

©2023 Amgen Inc. All rights reserved. USA-451-80031 8/23

Generalized pustular psoriasis is a rare inflammatory skin disease that can be life-threatening if left untreated, and treatment typically involves the use of therapies approved for plaque psoriasis. However, that could all be changing thanks to the recent understanding of IL-36’s role in generalized pustular psoriasis and the development of the treatment option spesolimab. Learn more with Dr. Raj Chovatiya and Dr. Jason Hawkes, medical dermatologist in the Greater Sacramento area who also sits on the National Psoriasis Foundation Medical Board and Scientific Advisory Committee.

Roflumilast and tapinarof are two of the new topical nonsteroidal therapies for plaque psoriasis that have several advantages over the traditional topical steroids. Learn more about how emerging topical nonsteroidals could impact your patients with plaque psoriasis with Dr. Raj Chovatiya and Dr. Jason Hawkes, a medical dermatologist in the Greater Sacramento area who also sits on the National Psoriasis Foundation Medical Board and Scientific Advisory Committee.

The 5-year recurrence rates for stage IIB and IIC melanoma are up to 46%, but now new immunotherapy options are FDA-approved for the adjuvant treatment of stage IIB and IIC melanoma. Find out why this matters and hear Drs. Jason Luke and Tara Mitchell break down the latest data on treating stage IIB and IIC melanoma with adjuvant immunotherapy.

Two of the biggest trials were recently completed for the use of IL-17 inhibitors for treating hidradenitis suppurative (HS). So what data should we know about? In this episode, Dr. Raj Chovatiya is joined by Dr. Martina Porter, Dermatologist at Beth Israel Deaconess Medical Center and Assistant Professor of Dermatology at Harvard Medical School.

For patients with hidradenitis suppurativa (HS), the exact cause of the condition is still being researched. So what therapies are currently available to treat this painful condition? To discuss what you need to know, Dr. Raj Chovatiya is joined by Dr. Martina Porter, Dermatologist at Beth Israel Deaconess Medical Center and Assistant Professor of Dermatology at Harvard Medical School.

The future looks promising for alopecia areata patients as two JAK inhibitors have been tested in clinical trials while other treatment studies are ongoing. So what should clinicians know about these therapies? Learn more as Dr. Raj Chovatiya speaks to Dr. Britt Craiglow, Adjunct Associate Professor at the Yale School of Medicine and Double Board-Certified Dermatologist with Dermatology Physicians of Connecticut.

Initially approved for the treatment of rheumatoid arthritis, baricitinib is now the first FDA-approved treatment for patients with alopecia areata. So what can patients look forward to with this new therapy? Dive in with Dr. Raj Chovatiya as he’s joined by Dr. Britt Craiglow, Adjunct Associate Professor at the Yale School of Medicine and Double Board-Certified Dermatologist at Dermatology Physicians of Connecticut.

Proper access to medication can present challenges for the doctor and patient but is necessary to achieve optimal patient outcomes. So how can they work together to eliminate this burden? To discuss this further, Dr. Mary Katherine Cheeley is joined by Dr. Justin Cheeley, Assistant Professor in the Departments of General Internal Medicine and Dermatology and the Director of Inpatient Dermatology at Emory School of Medicine.

Patients with IBD, arthritis, or other disorders of the immune system may be at a higher risk for developing pyoderma gangrenosum (PG). So how can clinicians better manage their patients with PG? Explore this rare condition as Dr. Mary Katherine Cheeley is joined by Dr. Justin Cheeley, Assistant Professor in the Departments of General Internal Medicine and Dermatology and the Director of Inpatient Dermatology at the Emory School of Medicine.

Getting the proper treatment for patients with psoriasis and psoriatic arthritis can be life-changing. So how can clinicians help patients find the right medication? To discuss this topic together, Dr. Matthew Keller is joined by fellow ReachMD host, Dr. Monica Schwartzman, who is also a Rheumatologist.

Physician assistants (PAs) are licensed to practice medicine to provide many of the same services as a physician. And they may even train in dermatology. But what do we need to take into consideration when bringing a PA into a dermatology practice? Joining Dr. Michael Greenberg to discuss the ethics of this all-too-common situation is Dr. John Weiss, President and Co-Managing Partner at Georgia Dermatology Partners.